#cartcelltherapy Dual acting CAR T-cell therapy The more the epitopes the stronger and better the effect. Be it for COVID vaccines or for polyclonal antibodies or for CAR T Cell therapies the universal rule do not let the target go which is only possible by effective binding.
Duel-Acting CAR T-Cell Therapy May Address Unmet Need in the Treatment of Patients with B-Cell Malignancies Cokey Nguyen is the chief scientific and technical officer at Atara Biotherapeutics, and he joins Pharmacy Times to discuss ATA3431, a novel duel-acting chimeric antigen receptor (CAR) that has undergone preclinical studies for the treatment of B-cell malignancies. Nguyen discusses the glass ceiling of some of the current single antigen-targeting CAR T therapies, the necessity for scaleable and accessible therapies, the importance of CD20 expression as a target for recurrent disease, and increased efficacy and safety benefits that may be associated with this new CAR therapeutic and its development.